Cabozantinib for Recurrent or Progressive Meningioma
This study is testing a drug called Cabozantinib for people with meningioma, a type of brain tumor, that has come back or gotten worse. You might be able to join if you are 18 or older, have a meningioma diagnosis (any grade), and your tumor has recurred or progressed after standard treatments like radiation or surgery, or if you can't receive those treatments. The main goal is to see how long people live without their disease getting worse (progression-free survival) at 6 months. This study plans to enroll 24 participants.
- Study design
- This is a Phase II interventional study, meaning it tests a specific treatment. It plans to enroll 24 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study measures progression-free survival at 6 months, which suggests follow-up for at least that long.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Cabozantinib for Patients With Recurrent or Progressive Meningioma
At a glance
Conditions
Where it's being run
3 sites across 3 statesStudy leadership
- Rupesh Kotecha, M.D. · PRINCIPAL_INVESTIGATOR · Miami Cancer Institute at Baptist Health, Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Progression free survival (PFS)6 months
PFS is defined as the proportion of participants who from the start of treatment are free from objective tumor progression or death from any cause at 6 months. Tumor response and progression will be assessed using Response Assessment in Neuro-Oncology (RANO) meningioma criteria. Progressive disease (PD) is defined as the presence of any of the following criteria: ≥ 25% increase in target lesion area relative to nadir, unequivocal progression of any nontarget lesion, presence of new lesions, or worsening clinical status. Participants without documented progression or death by 6 months will be censored at the date of their last adequate disease assessment. Those who discontinue early or are lost to follow-up prior to 6 months without a progression event will be censored at their last tumor assessment. Suspected but unconfirmed progression will not be counted as an event unless subsequently confirmed.